New Insulin Preparations: Potential Benefits And Risk Assessments
- ASU Author/Contributor (non-ASU co-authors, if there are any, appear on document)
- Dr.. Dana Brackney, Assistant Professor (Creator)
- Institution
- Appalachian State University (ASU )
- Web Site: https://library.appstate.edu/
Abstract: Concentrated insulins have been especially problematic high alert medications. On February 25, 2015 Federal Drug Administration (FDA) approval made available insulin glargine, Toujeo U-300 (300 units/ml) in a SoloSTAR pen. On May 27, 2015 the FDA approved insulin lispro, Humalog U-200 (200 units/ml) KwikPen. Increased incidence of insulin resistant type 2 diabetes has escalated the need for concentrated insulin. This paper discusses each insulin, appropriate patient selection, benefits of the new insulins for people with diabetes and providers, and suggestions for prevention of potential off-label use of insulin pens. Counseling and assessment are essential to avoid unintended harm.
New Insulin Preparations: Potential Benefits And Risk Assessments
PDF (Portable Document Format)
352 KB
Created on 10/17/2017
Views: 1366
Additional Information
- Publication
- Dana Brackney (2016). "New Insulin Preparations: Potential Benefits And Risk Assessments." The Journal for Nurse Practitioners. Volume 12, Issue #3. Version Of Record Available At: www.npjournal.org
- Language: English
- Date: 2016
- Keywords
- insulin, medication errors, nurse practitioners, risk assessment, type 2 diabetes, mellitus